Lartruvo

**Description**

Lartruvo (olaratumab)

**Background**

Lartruvo is used to treat soft tissue sarcoma (STS) in conjunction with doxorubicin for adult patients who have a histology that is not susceptible to curative treatment with surgery or radiotherapy. Lartruvo is a recombinant antibody that works by binding specifically to a tyrosine kinase receptor known as platelet-derived growth factor receptor alpha (PDGFR-α), which stimulates cell growth and differentiation. Lartruvo interrupts signal transduction of the receptor by preventing ligands from binding to PDGFR-α. This kinase receptor is detected on tumor cells including sarcomas where the signaling can lead to metastasis and cancer cell proliferation ultimately resulting in cancer progression (1).

**Regulatory Status**

FDA-approved indication: Lartruvo is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated, in combination with doxorubicin, for the treatment of soft-tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery (1).

Lartruvo can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use effective contraception while taking Lartruvo and for 3 months after completion or discontinuation of therapy (1).

The safety and effectiveness of Lartruvo in pediatric patients have not been established (1).
Lartruvo may be considered medically necessary in patients that are 18 years of age and older with soft tissue sarcoma (STS) and if the conditions indicated below are met.

Lartruvo is considered investigational in patients that are less than 18 years of age and for all other indications.

Prior-Approval Requirements

Age  
18 years of age or older

Diagnosis

Patient must have the following:

1. Soft Tissue Sarcoma (STS)

AND ALL of the following:

a. Histologic subtype for which an anthracycline-containing regimen is appropriate
b. Previous treatment failure with radiotherapy or surgery
c. Must be used in combination with doxorubicin for the first 8 cycles
d. If patient or their partner are of child bearing age, the patient has been or will be instructed to practice effective contraception during therapy and for 3 months after stopping therapy

Prior – Approval Renewal Requirements

Age  
18 years of age or older

Diagnosis

Patient must have the following:
1. Soft tissue sarcoma (STS)

**AND ALL** of the following:

a. **NO** disease progression or unacceptable toxicity
b. If patient or their partner are of child bearing age, the patient has been or will be instructed to practice effective contraception during therapy and for 3 months after stopping therapy

**Policy Guidelines**

**Pre - PA Allowance**
None

**Prior - Approval Limits**
Duration 12 months

**Prior – Approval ** *Renewal* Limits
Duration 12 months

**Rationale**

**Summary**
Lartruvo is a tyrosine kinase inhibitor indicated for the treatment of soft tissue sarcoma after trial of prior chemotherapy or surgery in patients with a histologic subtype that makes them appropriate candidates for treatment with anthracycline-containing regimens. Lartruvo should be used with caution in patients at risk for severe infusion-related reactions. This drug can cause fetal harm and women of reproductive age should use contraception. The safety and efficacy of Lartruvo in pediatric patients have not been studied (1).

Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Lartruvo while maintaining optimal therapeutic outcomes.

**References**
This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 20, 2019 and is effective on July 1, 2019.